scavenger receptor class F member 2Genealiases: NSR1 · SREC-II · SREC2 · SRECRP-1 · VDEGS
Q-omics provides the consensus-scored SCARF2 profile across patient tissues and cancer cell-line models. SCARF2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SCARF2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SCARF2 protein abundance shows 18,104 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, HNSC, and BRCA as cancer lineages where SCARF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCARF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCARF2 survival associations across molecular data types. SCARF2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCARF2 RNA expression–survival associations across cancer types. High SCARF2 expression shows unfavorable associations in ACC, BLCA, KIRP, MESO, THCA and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SCARF2 RNA expression.
This table summarizes SCARF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SCARF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCARF2 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, COAD, STAD and BRCA. The HNSC box plot shows higher SCARF2 RNA expression in tumor versus normal tissue (log2 FC = +1.604, t-test p < 0.001).
This table shows molecular features associated with SCARF2 in patient tissues and cancer cell lines. In patient samples, SCARF2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SCARF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
